| Drug ID: | Drug106 |
|---|---|
| Drug Name: | Artesunate |
| CID: | 6917864 |
| DrugBank ID: | DB09274 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT04713631 |
| Molecular Formula: | C19H28O8 |
| Molecular Weight: | 384.4 g/mol |
| Isomeric SMILES: | C[C@@H]1CC[C@H]2[C@H]([C@@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC(=O)CCC(=O)O)C |
| Synonyms: | Artesunate; Arsumax; Plasmotrin; Qinghaozhi; Saphnate; 88495-63-0; Artesunato; Artesunatum; Arinate; Dihydroqinghasu hemsuccinate |
| Phase 0: | 0 |
| Phase 1: | 33 |
| Phase 2: | 63 |
| Phase 3: | 68 |
| Phase 4: | 67 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt900 | 6917864 | Artesunate | None | -- | Plasmodium falciparum (malaria parasite P. falciparum) | 25126794 | Inhibitor |
| dt901 | 6917864 | Artesunate | 7364 | UGT2B7 | Homo sapiens (human) | 12167566 | Substrate |
| dt902 | 6917864 | Artesunate | 54600 | UGT1A9 | Homo sapiens (human) | 12167566 | Substrate |
| dt903 | 6917864 | Artesunate | 1548 | CYP2A6 | Homo sapiens (human) | 24891466 | Substrate |
| dt904 | 6917864 | Artesunate | 9429 | ABCG2 | Homo sapiens (human) | Substrate | |
| dt905 | 6917864 | Artesunate | 5243 | ABCB1 | Homo sapiens (human) | Substrate | |
| dt906 | 6917864 | Artesunate | 10599 | SLCO1B1 | Homo sapiens (human) | Inhibitor | |
| dt907 | 6917864 | Artesunate | 9376 | SLC22A8 | Homo sapiens (human) | Inhibitor | |
| dt908 | 6917864 | Artesunate | 213 | ALB | Homo sapiens (human) | 23684544 | Binder |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT04713631 | Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease | PHASE2 | RECRUITING | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Crohn's Disease | DRUG: Artesunate|DRUG: Curcumin|DRUG: Placebo A|D… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
A Randomized Double-Blind, Placebo-Controlled Trial of Artesunate and Curcumin …
PMID: 40589768
Year: 2025
Relationship Type:
Treatment
Score: 6.5
AIM: Less than half of all patients with Crohn's disease remain in remission with long-term use of azathioprine. Our aim was to assess the efficacy o…
Artesunate alleviated murine ulcerative colitis by regulating immune response t…
PMID: 40079012
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Innate and adaptive immunity are intricately linked to the pathogenesis of ulcerative colitis (UC), with dysregulation of the Treg/Th17 balance and M…
Chitosan-coated artesunate protects against ulcerative colitis via STAT6-mediat…
PMID: 37890744
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Oral delivery of chitosan-coated artesunate (CPA) has been proven to be effective at preventing ulcerative colitis (UC) in mice. However, the anti-in…
Artesunate alleviates the inflammatory response of ulcerative colitis by regula…
PMID: 33524272
Year: 2021
Relationship Type:
Treatment
Score: 6.5
CONTEXT: Ulcerative colitis (UC) is a recrudescent and chronic inflammatory disease. Artesunate (ART) has shown its anti-inflammatory and antioxidati…
Artesunate ameliorates DSS-induced ulcerative colitis by protecting intestinal …
PMID: 31897917
Year: 2020
Relationship Type:
Treatment
Score: 6.5
There are very few reports on the protective effect of artesunate (ARS) in ulcerative colitis (UC). This study focused on the efficacy of ARS on inte…
Artesunate exerts protective effects against ulcerative colitis via suppressing…
PMID: 31173225
Year: 2019
Relationship Type:
Treatment
Score: 6.5
Artesunate (ART) is a semi‑synthetic derivative of artemisinin used in the treatment of patients with malaria, which has also been reported to have i…
Immunomodulatory and anti-inflammatory properties of artesunate in experimental…
PMID: 22834815
Year: 2012
Relationship Type:
Treatment
Score: 6.1
BACKGROUND: Inflammatory bowel disease is a chronic and idiopathic gastrointestinal inflammation mediated by disregulated immune responses. Artemisin…